| 注册
首页|期刊导航|国际医药卫生导报|降纤治疗超急性期脑梗死临床再评价-前瞻性随机对照研究

降纤治疗超急性期脑梗死临床再评价-前瞻性随机对照研究

李又佳 黄燕 付耀高 徐安定 古志辉 林本 李福祥 潘小兰

国际医药卫生导报2010,Vol.16Issue(2):135-138,4.
国际医药卫生导报2010,Vol.16Issue(2):135-138,4.DOI:10.3760/cma.j.issn.1007-1245.2010.02.002

降纤治疗超急性期脑梗死临床再评价-前瞻性随机对照研究

Defibrination on treatment of acute cerebral infarction of internal carotid artery system:a prospectire randomized controlled trial

李又佳 1黄燕 1付耀高 2徐安定 2古志辉 1林本 1李福祥 1潘小兰1

作者信息

  • 1. 526021,肇庆市第一人民医院神经内科
  • 2. 510630,广州,暨南大学附属第一医院神经内科
  • 折叠

摘要

Abstract

Objective To evaluate the efficacy and safety of the defibrinogenating agent Batroxobin for patients with acute cerebral infarction( ACI) of internal carotid artery system( ICAS) within 24 hours of ictus.Methods 150 patients with ACI of ICAS within 24 hours of ictus were included in this randomized placebo-controlled trial.Brain CT scans were done to exclude intracranial haemorrhages.Patients were randomly divided into Batroxobin group ( n=75 ) and placebo group ( n=75 ).The primary outcome was the death rate, obvious dependent survival status ( Barthel Index ≤ 60) and disability ( modified Rankin Scale ≥ 3 ) at the third month and sixth month.The National Institutes of Health Stroke Scale was used as secondary endpoinls.Results Mortality was not different between treatment groups (in 6 months, 4.0% for the Batroxobin group and 2.7% for the placebo group, P=1.00, RR=1.50, 95%CI: 0.26~8.72 ).The proportion of obvious dependent survival status and death or disability did not differ between patients given Batroxobin and those given placebo at 3 months ( 23.6% vs 38.4%, P=0.055, RR=0.49, 95%CI:0. 24~1.02 and 33.3% vs 46.7%, P=0.096, RR=0.57, 95%CI:0.29~ 1.11 ).In the 180th day after the therapy, the Batroxobin group showed a remarkable improvement in obvious dependent survival status and death or disability ( 16.7% vs 32.9%, P=0.024, RR=0.41, 95%CI: 0.19 ~ 0.89 and 24.0% vs 40.0%, P=0.022, RR=0.44,95%CI: 0.22 ~ 0.89 ).No symptomatic intracranial hemorrhages were observed in two groups.There was a trend toward more extracranial hemorrhages in the Batroxobin group vs placebo group ( 16.0% vs 5.3%, P=.034, RR=3.00, 95%CI: 1.01~8.88 ). Conclusions This study showed that it appears safe and effective of defibrination on treatment of ACI of 1CAS within 24 hours of ictus.

关键词

巴曲酶/脑梗死/颈内动脉系统/随机对照试验

Key words

Batroxobin/Cerebral infarction Internal carotid artery system/Randomized controlled trial

引用本文复制引用

李又佳,黄燕,付耀高,徐安定,古志辉,林本,李福祥,潘小兰..降纤治疗超急性期脑梗死临床再评价-前瞻性随机对照研究[J].国际医药卫生导报,2010,16(2):135-138,4.

基金项目

广东省医学科研基金项目(B2006138) (B2006138)

国际医药卫生导报

1007-1245

访问量0
|
下载量0
段落导航相关论文